News
The stock has been in free fall since safety issues derailed a gene therapy analysts had expected to achieve blockbuster ...
Jefferies analysts said these detailed safety outcomes confirm the gene therapy's positive risk/benefit profile in ambulatory ...
Liquidating its stake in Arrowhead helps Sarepta cover a milestone payment and secure what one analyst described as ...
Sarepta sells $174M in Arrowhead shares to fund a $100M milestone payment as part of its RNAi drug collaboration.
A well-connected drug company and Laura Loomer wanted Kennedy ally Vinay Prasad gone. Trump chief of staff Susie Wiles got ...
Sarepta Therapeutics said Friday that the deaths of two patients taking its marketed gene therapy Elevidys® (delandistrogene ...
2d
MarketBeat on MSNBrutal 2025 for Sarepta—Analysts Still Call for 179% Upside
Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including charting and trades.
After two patients who received the investigational CDC7 blocker died, pushing forward with SGR-2921’s development would be ...
Vor Bio appoints Dallan Murray as chief commercial officer, leveraging his extensive experience to drive commercialization ...
Vinay Prasad, M.D., has rejoined the FDA, the latest turn in a monthslong stretch of leadership turnover at the agency. | “At ...
Sarepta Therapeutics is selling off Arrowhead Pharmaceuticals’ shares to stretch its cash runway, while also inking a share ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results